Vulnerability of health to market forces

Medical Care

Volumn 49, Issue 3, 2011, Pages 232-239

  Brezis, Mayer ^a   Wiist, William H ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NORTHERN ARIZONA UNIVERSITY   (United States)

Author keywords

corporations; free market; health care industry; pharmaceutical industry; public health

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG INDUSTRY; DRUG MARKETING; FINANCIAL MANAGEMENT; HEALTH CARE; HEALTH CARE COST; HEALTH CARE INDUSTRY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH HAZARD; PRIORITY JOURNAL; PROFIT; SOCIAL ASPECT;

DELIVERY OF HEALTH CARE; DRUG INDUSTRY; HEALTH CARE COSTS; HEALTH CARE SECTOR; HUMANS; MARKETING OF HEALTH SERVICES; POLITICS; PUBLIC HEALTH; PUBLIC POLICY; QUALITY OF HEALTH CARE; UNITED STATES;

EID: 79951674235     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e31820ab638     Document Type: Article

References (108)

1. Reich RB. Supercapitalism: The Transformation of Business, Democracy, and Everyday Life. New York, NY: Alfred A. Knopf; 2007.
2. American College of Physicians. Achieving a high-performance health care system with universal access: what the United States can learn from other countries. Ann Intern Med. 2008;148:55-75.
3. Brownlee S. Overtreated: Why Too Much Medicine is Making Us Sicker and Poorer. New York, NY: Bloomsbury; 2007.
4. Relman AS. A Second Opinion: Rescuing America's Health Care: A Plan for Universal Coverage Serving Patients Over Profit. New York, NY: Public Affairs; 2007.
5. Rosenau PV, Linder SH. Two decades of research comparing for-profit and no (Pubitemid 36737556)
6. Woolhandler S, Campbell T, Himmelstein DU. Costs of health care administration in the United States and Canada. N Engl J Med. 2003;349:768-775. (Pubitemid 37010782)
7. Devereaux PJ, Choi PT, Lacchetti C, et al. A systematic review and meta-analysis of studies comparing mortality rates of private for-profit and private not-for-profit hospitals. CMAJ. 2002;166:1399-1406. (Pubitemid 34539356)
8. Garg PP, Frick KD, Diener-West M, et al. Effect of the ownership of dialysis facilities on patients' survival and referral for transplantation. N Engl J Med. 1999;341:1653-1660.
9. Thamer M, Zhang Y, Kaufman J, et al. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA. 2007;297: 1667-1674. (Pubitemid 46631625)
10. Harrington C, Woolhandler S, Mullan J, et al. Does investor ownership of nursing homes compromise the quality of care? Am J Public Health. 2001;91:1452-1455. (Pubitemid 32803333)
11. Dalen JE. Health care in America: the good, the bad, and the ugly. Arch Intern Med. 2000;160:2573-2576.
12. Callahan D, Wasunna AA. Medicine and the Market: Equity v. Choice. Baltimore, MD: Johns Hopkins University Press; 2006.
13. Arrow KJ. Uncertainty and the welfare economics of medical care. Am Econ Rev. 1963;53:941-973.
14. Mahar M. Money driven medicine: the real reason health care costs so much. New York, NY: Collins; 2006.
15. Porter ME, Teisberg EO. Redefining Health Care: Creating Value-Based Competition on Results. Boston, MA: Harvard Business School Press; 2006.
16. Starfield B, Leiyu S, Macinko J. Contribution of primary care to health systems and health. Milbank Q. 2005;83:457-502. (Pubitemid 41551756)
17. Woo B. Primary care-the best job in medicine? N Engl J Med. 2006;355:864-866. (Pubitemid 44315977)
18. Wennberg JE, Fisher ES, Skinner JS. Geography and the debate over Medicare reform. Health Aff. 2002;13:2579-2584.
19. Oberlander J. The US health care system: on a road to nowhere? CMAJ. 2002;167:163-168. (Pubitemid 34791527)
20. Iglehart JK. Building momentum as Democrats forge health care reform. N Engl J Med. 2009;360:2385-2387.
21. Abramson J. Overdosed America: The Broken Promise of American Medicine. New York, NY: HarperCollins; 2004.
22. Angell M. The Truth About the Drug Companies: How They Deceive Us and What To Do About It. New York, NY: Random House; 2004.
23. Smith R. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med. 2005;2:e138.
24. Deyo RA, Patrick DL. Hope or Hype: The Obsession With Medical Advances and the High Cost of False Promises. New York, NY: AMACOM, American Management Association; 2005.
25. Avorn J. Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs. New York, NY: Knopf; 2004.
26. Als-Nielsen B, Chen W, Gluud C, et al. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA. 2003;290:921-928. (Pubitemid 37430464)
27. Melander H, Ahlqvist-Rastad J, Meijer G, et al. Evidence b (i) ased medicine-selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003; 326:1171-1173. (Pubitemid 36649049)
28. Yank V, Rennie D, Bero LA. Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study. BMJ. 2007;335:1202-1205. (Pubitemid 350273305)
29. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ. 2006;332:699-703.
30. Healy D. Let Them Eat Prozac: The Unhealthy Relationship Between the Pharmaceutical Industry and Depression. New York, NY: New York University Press; 2004.
31. Silverman MM, Lee PR. Pills, Profits, and Politics. Berkeley, CA: University of California Press; 1974.
32. Juni P, Reichenbach S, Egger M. COX 2 inhibitors, traditional NSAIDs, and the heart. BMJ. 2005;330:1342-1343. (Pubitemid 40839557)
33. Kesselheim AS, Mello MM. Confidentiality laws and secrecy In medical research: improving public access to data on drug safety. Health Aff. 2007;26:483-491.
34. Topol EJ. Failing the public health-rofecoxib, Merck, and the FDA. N Engl J Med. 2004;351:1707-1709. (Pubitemid 39383201)
35. Abramson J, Starfield B. The effect of conflict of interest on biomedical research and clinical practice guidelines: can we trust the evidence in evidence-based medicine? J Am Board Fam Pract. 2005;18:414-418. (Pubitemid 41663987)
36. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358:252-260.
37. Waxman HA. The lessons of Vioxx-drug safety and sales. N Engl J Med. 2005;352:2576-2578.
38. Drazen JM, Wood AJ. Don't mess with the DSMB. N Engl J Med. 2010;363:477-478.
39. Kassirer JP. On the Take: How America's Complicity With Big Business Can Endanger Your Health. New York, NY: Oxford University Press; 2005.
40. Moynihan R. Blurring the boundaries. BMJ. 2003;326:1094.
41. Moynihan R, Cassels A. Selling Sickness: How the World's Biggest Pharmaceutical Companies are Turning Us All Into Patients. New York, NY: Nation Books; 2005.
42. Moynihan R, Henry D. The fight against disease mongering: generating knowledge for action. PLoS Med. 2006;3:e191.
43. Okie S. Raising the safety bar-the FDA's coxib meeting. N Engl J Med. 2005;352:1283-1285. (Pubitemid 40411491)
44. Lobbying database, Center for responsive politics. Available at: http:// www.opensecrets.org/ Accessed February 7, 2008.
45. Fugh-Berman A, Ahari S. Following the script: how drug reps make friends and influence doctors. PLoS Med. 2007;4:e150.
46. Brody H. Hooked: Ethics, the Medical Profession, and the Pharmaceutical Industry. Lanham, MD: Rowman & Littlefield; 2007.
47. Brezis M. Big pharma and health care: unsolvable conflict of interests between private enterprise and public health. Isr J Psychiatry Relat Sci. 2008;45:83-89; discussion 90-84.
48. Moncrieff J. Psychiatric drug promotion and the politics of neoliber-alism. Br J Psychiatry. 2006;188:301-302.
49. Cohen D. Needed: critical thinking about psychiatric medications. Soc Work Ment Health. 2009;7:42-61.
50. Phillips CB. Medicine goes to school: teachers as sickness brokers for ADHD. PLoS Med. 2006;3:e182.
51. Jureidini J, Tonkin A. Overuse of antidepressant drugs for the treatment of depression. CNS Drugs. 2006;20:623-632. (Pubitemid 44141490)
52. Suaya JA, Shepard DS, Normand SL, et al. Use of cardiac rehabilitation by Medicare beneficiaries after myocardial infarction or coronary bypass surgery. Circulation. 2007;116:1653-1662. (Pubitemid 47537840)
53. Chivu CM, Soares-Weiser K, Braunstein R, et al. Systematic review of interventions to increase periconceptional awareness, knowledge and consumption of folic acid supplements. Am J Health Promot. 2008;22: 237-243.
54. Smith SC, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention: a report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines endorsed by the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol. 2001;37:2239.
55. Solberg LI, Maciosek MV, Edwards NM, et al. Repeated tobacco-use screening and intervention in clinical practice: health impact and cost effectiveness. Am J Prev Med. 2006;31:62-71.
56. Ades PA. Cardiac rehabilitation and secondary prevention of coronary heart disease. N Engl J Med. 2001;345:892.
57. Thorndike AN, Regan S, Rigotti NA. The treatment of smoking by US physicians during ambulatory visits: 1994 2003. Am J Public Health. 2007;97:1878-1883. (Pubitemid 351182301)
58. Albright A, Franz M, Hornsby G, et al. American College of Sports Medicine position stand. Exercise and type 2 diabetes. Med Sci Sports Exerc. 2000;32:1345-1360.
59. Mellen PB, Palla SL, Goff DC, et al. Prevalence of nutrition and exercise counseling for patients with hypertension. J Gen Intern Med. 2004;19:917-924. (Pubitemid 39244507)
60. Fischer M.A., Avorn J. Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA, 2004, 291, 1850-1856. (Pubitemid 38509497)
61. Bush RW. Reducing waste in US health care systems. JAMA. 2007; 297:871-874. (Pubitemid 46333952)
62. Ayres R, Kneese A. Production, consumption, and externalities. Am Econ Rev. 1969;59:282-297.
63. Cohen JE, Ashley MJ, Ferrence R, et al. Institutional addiction to tobacco. Tob Control. 1999;8:70-74.
64. Michaels D. Doubt is Their Product: How Industry's Assault on Science Threatens Your Health. New York, NY: Oxford University Press; 2008.
65. Markowitz GE, Rosner D. Deceit and Denial: The Deadly Politics of Industrial Pollution. Berkeley, CA: University of California Press; 2002.
66. Nestle M. Food Politics: How the Food Industry Influences Nutrition and Health. Berkeley, CA: University of California Press; 2002.
67. Mobley L, Root E, Finkelstein E, et al. Environment, obesity, and cardiovascular disease risk in low-income women. Am J Prev Med. 2006;30:327.
68. Labbok M. Commercial infant foods and lactation devices: marketing, misuse, and mortality. Paper presented at: 135th Annual Meeting, American Public Health Association, 2007; Washington, DC.
69. Huff J. Industry influence on occupational and environmental public health. Int J Occup Environ Health. 2007;13:107-117. (Pubitemid 46466627)
70. Jahiel RI, Babor TF. Industrial epidemics, public health advocacy and the alcohol industry: lessons from other fields. Addiction. 2007;102: 1335-1339. (Pubitemid 47246982)
71. Linn S. Consuming kids: The hostile takeover of childhood. New York, NY: New Press; 2004. See also film: Consuming Kids The Commercialization of Childhood. Available at: http://www.mediaed.org/cgi-bin/ commerce.cgi?preadd= action&key=134.
72. McAllister M. From flick to flack: the increased emphasis on marketing by media entertainment corporations. In: Anderson R, Strate L, eds. Critical Studies in Media Commercialism. New York, NY: Oxford University Press; 2000:101-122.
73. Charlesworth A, Glantz S. Smoking in the movies increases adolescent smoking: a review. Pediatrics. 2005;116:1516.
74. Schor J, Ford M. From tastes great to cool: children's food marketing and the rise of the symbolic. J Law Med Ethics. 2007;35:10-21.
75. Harris J, Pomeranz J, Lobstein T, et al. A crisis in the marketplace: how food marketing contributes to childhood obesity and what can be done. Annu Rev Public Health. 2009;30:211-225.
76. Weber LJ. Profits Before People? Ethical Standards and the Marketing of Prescription Drugs. Bloomington, IN: Indiana University Press; 2006.
77. Armstrong JS. Social irresponsibility in management. J Bus Res. 1977;5:185-213.
78. Piquero NL, Tibbetts SG, Blankenship MB. Examining the role of differential association and techniques of neutralization in explaining corporate crime. Deviant Behav. 2005;26:159-188. (Pubitemid 40306068)
79. Dodd EM Jr. For whom are corporate managers trustees? Harv Law Rev. 1932;45:1145-1163.
80. Smith AD. Making the case for the competitive advantage of corporate social responsibility. Business Strategy Series. 2007;8:186-195.
81. Wiist W. Corporate strategies to influence trade and health policies. Paper presented at: American Public Health Association Annual Meeting, 2007; Washington, DC.
82. Wiist WH. The corporation: an overview of what it is, its tactics and what public health can do. In: Wiist WH, ed. The Bottom Line or Public Health: Tactics, Corporations Use to Influence Health and Health Policy, and What We Can Do to Counter Them. New York, NY: Oxford University Press; 2010.
83. Krimsky S. Science in the Private Interest: Has the Lure of Profits Corrupted Biomedical Research? Lanham, MD: Rowman & Littlefield Publishers; 2003.
84. Cowling K, Tomlinson PR. Globalisation and corporate power. Contrib Pol Econ. 2005;24:33-54. (Pubitemid 41222466)
85. Wiist WH. Public health and the anticorporate movement: rationale and recommendations. Am J Public Health. 2006;96:1370-1375. (Pubitemid 44198657)
86. Arnold PJ, Reeves TC. International trade and health policy: Implications of the GATS for US healthcare reform. J Bus Ethics. 2006;63: 313-332. (Pubitemid 43208528)
87. Desbordes R, Vauday J. The political influence of foreign firms in developing countries. Econom Polit. 2007;19:421-451. (Pubitemid 47604447)
88. Korten DC. The Great Turning: From Empire to Earth Community. San Francisco, CA: Berrett-Koehler; 2006.
89. Heavey S. Healthcare lobby set for record spending this year. 2009. Available at: http://www.reuters.com/article/gc07/idUSTRE5AJ3 HA20091120. Accessed December 11, 2009.
90. Connolly C. Health insurers emerge as Obama's top foe in reform effort. Washington Post, October 14, 2009. Available at: http://www. washingtonpost.com/wp-dyn/content/article/2009/10/13/AR2009101303472. htm?hpid=topnews. Accessed December 11, 2009.
91. Eggen D. Lobbyist spend millions to influence health care. Washington Post, July 21, 2009. Available at: http://voices.washingtonpost.com/ health-care-reform/2009/07/health-care-continues-its-inte.html. Accessed December 11, 2009.
92. Israel J, Mehta A. Blue Dogs fill their bowls with cash: Moderate Democratic coalition's leverage draws interest across the spectrum. July 23, 2009. Available at: http://www.publicintegrity.org/articles/ entry/1572/. Accessed December 11, 2009.
93. Open Secrets. Pharmaceutical Research and Manufacturers of America. 2009. Available at: http://www.opensecrets.org/orgs/all-summary.php? id=D000000504&nid=4265. Accessed December 11, 2009.
94. Open Secrets. Senate Finance Committee 111th Congress (2010 cycle): Overview. 2009. Available at: http://www.opensecrets.org/cmteprofiles/ overview.php?cmte=SFIN&cmteid=S12&cycle=2010. Accessed December 11, 2009.
95. Open Secrets. Max Baucus. Top Industries, 2005-2010 Campaign Committee. 2009. Available at: http://www.opensecrets.org/politicians/ summary.php?cycle= 2010&type=I&cid=N00004643. Accessed December 11, 2009.
96. Sachs J. America's broken politics. The Guardian, November 23, 2009. Available at: http://www.guardian.co.uk/commentisfree/2009/nov/23/ us-government-tax-reform-crisis. Accessed December 11, 2009.
97. Marmot M. Social determinants of health inequalities. Lancet. 2005; 365:1099-1104. (Pubitemid 40386787)
98. Wilkinson R, Marmot M. Social determinants of health: the solid facts. Copenhagen, Denmark: World Health Organization (2003). Available at: http://wwweurowhoint/ data/assets/pdf file/0005/98438/e81384pdf Accessed August 23, 2010.
99. Adelman L. Unnatural causes: is inequality making us sick? Prev Chronic Dis. 2007;4:1-2.
100. Starfield B. Pathways of influence on equity in health. Soc Sci Med. 2007;64:1355-1362. (Pubitemid 46349393)
101. Sachs J. Common Wealth: Economics for a Crowded Planet. New York, NY: Penguin Press; 2008.
102. Stuckler D, King L, McKee M. Mass privatisation and the post-communist mortality crisis: a cross-national analysis. Lancet. 2009; 373:399-407.
103. Krieger N, Birn AE. A vision of social justice as the foundation of public health: commemorating 150 years of the spirit of 1848. Am J Public Health. 1998;88:1603.
104. Smith A, Cannan E, Lerner M. An Inquiry Into the Nature and Causes of the Wealth of Nations (1776). New York, NY: The Modern Library; 1937:60-61, 123.
105. Marx M, Margil M, Cavanagh J, et al. Strategic Corporate Initiative: Toward a Global Citizens' Movement to Bring Corporations Back Under Control. 2007. Available at: http://www.corpethics.org/downloads/ SCI-Report-September- 2007.pdf Accessed December 11, 2009.
106. Moses H III, Martin JB. Academic relationships with industry: a new model for biomedical research. JAMA. 2001;285:933-935. (Pubitemid 32171555)
107. Budetti PP. Market justice and US health care. JAMA. 2008;299:92-94.
108. Kuttner R. Market-based failure-a second opinion on U.S. health care costs. N Engl J Med. 2008;358:549-551. (Pubitemid 351214281)